The Chronic Obstructive Pulmonary Disease Drugs Market is being driven by Rising prevalence of COPD
The Chronic Obstructive Pulmonary Disease Drugs Market is expected to grow at a CAGR of 6.24% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 7193.4 million. In the COPD drugs market, there is a pressing need for innovative therapeutic solutions to effectively manage the disease's progressive nature. Researchers are actively investigating molecular targets responsible for COPD progression to develop novel biologic therapies, such as monoclonal antibodies. Despite initial regulatory challenges, these treatments hold promise. For instance, Johnson & Johnson's CNTO 6785, a monoclonal antibody in Phase II trials, targets interleukin 17A proteins, potentially slowing or halting disease progression in COPD patients. Other similar products are also in development.
Get more information on Chronic Obstructive Pulmonary Disease Drugs Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
168 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6.24% |
|
Market growth 2024-2028 |
USD 7193.4 million |
|
Market structure |
fragmentation |
|
YoY growth 2023-2024(%) |
5.49 |
|
Key countries |
US, UK, Canada, Germany, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that requires specialized treatment and long-term care. COPD management focuses on improving quality of life, disease outcomes, and slowing down disease progression. Traditional treatment approaches include bronchodilators, corticosteroids, and oxygen therapy. However, innovative therapies such as pulmonary rehabilitation, lung volume reduction surgery, and lung transplantation are also effective. COPD is often caused by indoor air pollution, workplace pollution, and smoking tobacco. The disease burden is particularly high in underdeveloped and developing countries due to high levels of indoor air pollution and tobacco consumption. Recognition and diagnosis of COPD are crucial for effective treatment, and medical knowledge and diagnostic tools continue to advance. Governments and healthcare systems play a significant role in COPD management by investing in research, treatments, and diagnostic tools. Expenditure on healthcare for COPD is expected to increase due to the aging population and rising tobacco consumption among the youth. Generic drugs offer an affordable alternative to expensive branded medications, making COPD treatment more accessible. Innovative therapies, such as gene therapy and stem cell therapy, are under investigation to provide better treatment options for COPD patients. Overall, continued research and investment in COPD management are essential to improve outcomes and reduce the burden of this chronic disease.
According to Technavio, the global Chronic Obstructive Pulmonary Disease (COPD) drugs market is a segment of the larger pharmaceuticals market within the healthcare industry. The pharmaceuticals market encompasses entities involved in research and development (R&D) or manufacturing of various drug categories, including generic, non-generic, and veterinary drugs. The healthcare industry's overall size is determined by Technavio based on the consolidated revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Key growth drivers for the healthcare market include the increasing elderly population, with the global population aged 60 years and above projected to experience substantial growth.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
